Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Core Insights - Oragenics, Inc. has engaged DUCK FLATS Pharma to support its U.S. Investigational New Drug (IND) readiness and regulatory execution for its novel intranasal concussion therapy, ONP-002, as it prepares for clinical trials in the U.S. [1][2] - The collaboration aims to ensure regulatory diligence and trial integrity, aligning the upcoming Phase 2a clinical trial in Australia with U.S. regulatory strategies [1][2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [5] - The lead candidate, ONP-002, is being advanced as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing Phase 2a trials in Australia and plans for U.S. Phase 2b trials [5] Market Potential - The global concussion market is projected to exceed $9 billion by 2027, indicating significant growth potential for innovative therapies in this area [4] - The nasal drug delivery market is expected to reach over $125 billion by 2030, highlighting the broader market opportunity for intranasal therapeutics [4] Collaboration Details - DUCK FLATS Pharma has a strong track record, having contributed to the development and approval of approximately 40 drug programs, including notable intranasal therapies [2][3] - The firm has extensive experience in regulatory and drug development, having managed over 400 regulatory documents and served as project lead on more than 60 FDA-approved New Drug Applications [2]